Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study

NCT02066454 is registered in ClinicalTrials.gov with University Hospital, Grenoble as lead sponsor.

NCT NCT02066454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02066454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study
Lead sponsor
University Hospital, Grenoble
Phase
Phase 3
Overall status
Completed
Start date
June 5, 2014
Completion date
July 12, 2016
Enrollment
108 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

myeloma, venous thromboembolism